ATG versus basiliximab induction therapy in kidney allograft recipients receiving dual immunosuppressive regimen: six‐year results

Category Primary study
JournalTransplantation
Year 2008
This article has no abstract
Epistemonikos ID: 72f2daf832679e14ec11a09ec95430e6f010f70a
First added on: Oct 26, 2018